OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Nov 15, 2024;25 (22):

Collateral Sensitivity to ��-Lactam Antibiotics in Evolved Apramycin-Resistant MRSA.

Jingjing Wu, Shiqian Wu, Juan Liu, Changmin Li, Mei Zheng, Fuhao Li, Yan Zhang, Yashuang Wu, Yang Yu
Author Information
  1. Jingjing Wu: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  2. Shiqian Wu: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  3. Juan Liu: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  4. Changmin Li: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  5. Mei Zheng: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  6. Fuhao Li: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  7. Yan Zhang: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  8. Yashuang Wu: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
  9. Yang Yu: State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou 510642, China.
PMID: 39596355 DOI: 10.3390/ijms252212292

Abstract

Collateral sensitivity is an evolutionary trade-off for bacteria where acquiring resistance to one antibiotic results in an increased sensitivity to another antibiotic. This study was designed to evaluate the collateral sensitivity of methicillin-resistant (MRSA) to ��-lactam antibiotics induced by the evolution of resistance to Apramycin. Collateral sensitivity to ampicillin, cephazolin, ceftriaxone, cefotaxime, cefepime and cefquinome occurred after MRSA were exposed to Apramycin and induced to acquire resistance. This sensitivity was associated with reduced ��-lactamase activity and decreased expression of the gene. We also found a decrease in the proton motive force and decreased efflux activity. These results provide new insights into collateral sensitivity-based strategies for the treatment of MRSA.

Keywords

apramycin collateral sensitivity methicillin-resistant Staphylococcus aureus ��-lactam antibiotics

References

  1. Antimicrob Agents Chemother. 2009 Jun;53(6):2266-73 [PMID: 19289521]
  2. Trends Microbiol. 2018 Aug;26(8):677-691 [PMID: 29439838]
  3. Nat Rev Dis Primers. 2018 May 31;4:18033 [PMID: 29849094]
  4. Curr Opin Microbiol. 1999 Oct;2(5):489-93 [PMID: 10508723]
  5. Science. 2016 Jan 1;351(6268):aad3292 [PMID: 26722002]
  6. J Bacteriol. 1952 Oct;64(4):489-99 [PMID: 12999676]
  7. Mol Syst Biol. 2013 Oct 29;9:700 [PMID: 24169403]
  8. Front Microbiol. 2018 Nov 27;9:2925 [PMID: 30538695]
  9. Antimicrob Agents Chemother (Bethesda). 1967;7:314-23 [PMID: 5596154]
  10. Med Res Rev. 2023 Jul;43(4):1068-1090 [PMID: 36896761]
  11. Antibiotics (Basel). 2023 Aug 24;12(9): [PMID: 37760659]
  12. Sci Rep. 2019 Feb 20;9(1):2410 [PMID: 30787404]
  13. Mol Biol Evol. 2017 Sep 1;34(9):2229-2244 [PMID: 28541480]
  14. Microb Pathog. 2017 Nov;112:122-125 [PMID: 28958949]
  15. Int J Antimicrob Agents. 2020 Feb;55(2):105864 [PMID: 31870598]
  16. Clin Infect Dis. 2021 Dec 16;73(12):2353-2360 [PMID: 33993226]
  17. Ann Clin Microbiol Antimicrob. 2006 Feb 09;5:2 [PMID: 16469106]
  18. Saudi J Biol Sci. 2023 Apr;30(4):103604 [PMID: 36936699]
  19. Nat Chem Biol. 2015 Nov;11(11):855-61 [PMID: 26368589]
  20. Antimicrob Agents Chemother (Bethesda). 1967;7:324-31 [PMID: 5596155]
  21. Emerg Microbes Infect. 2020 Dec;9(1):1628-1637 [PMID: 32619386]
  22. Front Cell Infect Microbiol. 2022 Jun 17;12:907314 [PMID: 35782148]
  23. Pharmacotherapy. 2017 Nov;37(11):1347-1356 [PMID: 28949410]
  24. J Antimicrob Chemother. 2019 Apr 1;74(4):944-952 [PMID: 30629184]
  25. Proc Natl Acad Sci U S A. 2016 May 3;113(18):5047-52 [PMID: 27091964]
  26. Int J Antimicrob Agents. 2021 Mar;57(3):106283 [PMID: 33503451]
  27. Drug Resist Updat. 2023 May;68:100961 [PMID: 37004351]
  28. Pathogens. 2024 Jan 15;13(1): [PMID: 38251383]
  29. Nature. 1961 Jul 8;191:144-8 [PMID: 13771349]
  30. Int J Antimicrob Agents. 2008 Jun;31(6):507-10 [PMID: 18180148]
  31. J Hosp Infect. 1988 Jul;12(1):29-34 [PMID: 2905371]
  32. Biotechnol Adv. 2019 Jan - Feb;37(1):177-192 [PMID: 30500353]
  33. Nat Rev Microbiol. 2009 Jun;7(6):460-6 [PMID: 19444248]
  34. Science. 2003 Nov 28;302(5650):1569-71 [PMID: 14645850]
  35. Vet Microbiol. 2010 Jan 6;140(1-2):176-9 [PMID: 19643555]
  36. Chem Biol. 2013 Sep 19;20(9):1168-78 [PMID: 23972939]
  37. Clin Microbiol Rev. 1997 Oct;10(4):781-91 [PMID: 9336672]
  38. Nat Rev Microbiol. 2009 Sep;7(9):629-41 [PMID: 19680247]
  39. Clin Infect Dis. 2019 Nov 27;69(12):2112-2118 [PMID: 30753447]
  40. Microb Drug Resist. 2020 May 14;: [PMID: 32401692]
  41. Antimicrob Agents Chemother. 2004 Aug;48(8):2871-5 [PMID: 15273094]
  42. Microbiol Spectr. 2022 Oct 26;10(5):e0139022 [PMID: 35972286]
  43. Lett Appl Microbiol. 2013 Sep;57(3):181-6 [PMID: 23659178]
  44. J Hosp Infect. 2022 Nov;129:41-48 [PMID: 35839999]
  45. Curr Med Chem. 2023;30(7):783-808 [PMID: 35726414]
  46. Nature. 2011 May 12;473(7346):216-20 [PMID: 21562562]
  47. PLoS Pathog. 2021 Jan 14;17(1):e1009172 [PMID: 33444399]
  48. Antimicrob Agents Chemother. 2011 Jan;55(1):373-5 [PMID: 20876371]
  49. Front Microbiol. 2020 Mar 13;11:425 [PMID: 32231657]
  50. Diagn Microbiol Infect Dis. 2018 Oct;92(2):168-171 [PMID: 29934071]
  51. Microb Drug Resist. 2021 Nov;27(11):1555-1559 [PMID: 33956523]
  52. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6693-7 [PMID: 6959147]
  53. Mol Microbiol. 2001 Apr;40(2):433-9 [PMID: 11309125]
  54. PLoS One. 2010 Dec 08;5(12):e15179 [PMID: 21209699]
  55. Sci Rep. 2020 Mar 3;10(1):3900 [PMID: 32127606]

Grants

  1. 32121004/the Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  2. 2019BT02N054/Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
  3. 2023YFD1800100/National key research and development program of China
  4. NT2021006/Laboratory of Lingnan Modern Agriculture Project
  5. 2022YFE0103200/National Key Research & Development Program of China
  6. 2023B10564003/Double first-class discipline promotion project
  7. D20008/the 111 Center
  8. No.32002337/the National Natural Science Foundation of China
  9. 2022A1515011194/the Natural Science Foundation of Guangdong Province, China
  10. 2023B0202150001/the Guangdong provincial key research and development program

MeSH Term

Methicillin-Resistant Staphylococcus aureus
Anti-Bacterial Agents
beta-Lactams
Nebramycin
Microbial Sensitivity Tests
Bacterial Proteins
beta-Lactamases
Penicillin-Binding Proteins
beta Lactam Antibiotics

Chemicals

Anti-Bacterial Agents
beta-Lactams
Nebramycin
apramycin
Bacterial Proteins
beta-Lactamases
Penicillin-Binding Proteins
mecA protein, Staphylococcus aureus
beta Lactam Antibiotics
Journal Article

Word Cloud

Created with Highcharts 10.0.0sensitivityMRSACollateralresistancecollateralapramycinantibioticresultsmethicillin-resistant��-lactamantibioticsinducedactivitydecreasedevolutionarytrade-offbacteriaacquiringoneincreasedanotherstudydesignedevaluateevolutionampicillincephazolinceftriaxonecefotaximecefepimecefquinomeoccurredexposedacquireassociatedreduced��-lactamaseexpressiongenealsofounddecreaseprotonmotiveforceeffluxprovidenewinsightssensitivity-basedstrategiestreatmentSensitivity��-LactamAntibioticsEvolvedApramycin-ResistantStaphylococcusaureus

Similar Articles

Cited By

No available data.